User profiles for Leah B. Soriaga

Leah Barrera Soriaga

Other name: Leah B. Soriaga
Bioinformatics
Verified email at perceptrove.com
Cited by 17301

[HTML][HTML] Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies

FA Lempp, LB Soriaga, M Montiel-Ruiz, F Benigni… - Nature, 2021 - nature.com
SARS-CoV-2 infection—which involves both cell attachment and membrane fusion—relies
on the angiotensin-converting enzyme 2 (ACE2) receptor, which is paradoxically found at low …

Lipid production in Nannochloropsis gaditana is doubled by decreasing expression of a single transcriptional regulator

I Ajjawi, J Verruto, M Aqui, LB Soriaga… - Nature …, 2017 - nature.com
Lipid production in the industrial microalga Nannochloropsis gaditana exceeds that of
model algal species and can be maximized by nutrient starvation in batch culture. However, …

Phylogenetic distribution of CRISPR-Cas systems in antibiotic-resistant Pseudomonas aeruginosa

A van Belkum, LB Soriaga, MC LaFave, S Akella… - MBio, 2015 - Am Soc Microbiol
Pseudomonas aeruginosa is an antibiotic-refractory pathogen with a large genome and
extensive genotypic diversity. Historically, P. aeruginosa has been a major model system for …

[HTML][HTML] Advances in genomics for drug development

R Spreafico, LB Soriaga, J Grosse, HW Virgin, A Telenti - Genes, 2020 - mdpi.com
Drug development (target identification, advancing drug leads to candidates for preclinical
and clinical studies) can be facilitated by genetic and genomic knowledge. Here, we review …

[HTML][HTML] Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice

…, S Jaconi, L Vincenzetti, H Imam, LB Soriaga… - Journal of …, 2023 - Elsevier
Background & Aims Chronic hepatitis B is a global public health problem, and coinfection
with hepatitis delta virus (HDV) worsens disease outcome. Here, we describe a hepatitis B

[PDF][PDF] Antibody therapy reverses biological signatures of COVID-19 progression

MC Maher, LB Soriaga, A Gupta, YP Chen, J di Iulio… - Cell Reports …, 2022 - cell.com
Understanding who is at risk of progression to severe coronavirus disease 2019 (COVID-19)
is key to clinical decision making and effective treatment. We study correlates of disease …

Antibody therapy reverses biological signatures of COVID-19 progression (preprint)

MC Maher, LB Soriaga, A Gupta, J di Iulio, S Ledoux… - 2021 - pesquisa.bvsalud.org
Understanding who is at risk of progression to severe COVID-19 is key to effective treatment.
We studied correlates of disease severity in the COMET-ICE clinical trial that randomized …

Electrochemical atomic layer deposition (E-ALD) of palladium nanofilms by surface limited redox replacement (SLRR), with EDTA complexation

…, JL Stickney, DB Robinson, MP Soriaga - Electrocatalysis, 2012 - Springer
Atomic-scale control in the formation of Pd thin films is being developed using electrochemical
atomic layer deposition (E-ALD) via surface limited redox replacement (SLRR). Pd has …

Imprinted antibody responses against SARS-CoV-2 Omicron sublineages

…, GD De Melo, L Kergoat, H Bourhy, J Neyts, L Soriaga… - Science, 2022 - science.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages carry
distinct spike mutations resulting in escape from antibodies induced by previous infection or …

[CITATION][C] Phylogenetic distribution of CRISPR-Cas systems in antibiotic-resistant Pseudomonas aeruginosa. mBio 6: e01796-15

A van Belkum, LB Soriaga, MC LaFave, S Akella… - 2015 - November